Evidence-first / Research-backed

The science of
GLP-1, GIP & GLP-3,
made clear.

Q: Does GLP3 Weight Loss prescribe peptide or provide care?

No. GLP3 Weight Loss is an independent informational resource and research-product catalog. We do not employ clinicians, see patients, prescribe, or dispense peptide. We can refer you to independent, third-party licensed providers who handle any evaluation, prescribing, and care.

Q: What is the Telos research-compound line?

Telos is our catalog of research-grade compounds sold strictly for laboratory and in-vitro research use only. These products are not for human or veterinary use, consumption, or therapeutic purposes, and are not approved by the FDA for treating any condition.

Q: How do I get a prescription if I'm interested in GLP-1 therapy?

Prescription peptides require evaluation by a licensed healthcare provider. We can refer you to independent third-party providers; whether a peptide is appropriate for you is solely between you and that provider. We are not party to that relationship and do not dispense peptide.

Q: What are the common side effects of GLP-1 peptides?

Commonly reported side effects include mild gastrointestinal symptoms such as nausea, which often lessens over time. Serious side effects are possible. This is general information only — discuss risks, contraindications, and monitoring with your own licensed provider before starting any peptide.

Independent, evidence-based education on semaglutide, tirzepatide, and next-generation retatrutide (GLP-3) research — plus research-use-only compounds. We connect you with independent licensed providers. We are not a medical provider.

See my options Explore the research

No obligation · Independent licensed providers · Educational use only

RUO

TELOS research-use-only peptide compounds — pens and vials, educational reference

148

Research compounds
catalogued

GLP pathways
explained

Peer-reviewedEvery claim cited

Not medical advice. Consult a licensed clinician before starting any protocol. Independent educational resource Referrals to independent licensed providers Compounds are research-use-only

Education for All 50 States

Plain-English Drug Science

Peer-Reviewed Sources

Research-Use-Only Compounds

Independent Provider Referrals

Education for All 50 States

Plain-English Drug Science

Peer-Reviewed Sources

Research-Use-Only Compounds

Independent Provider Referrals

How We Help

Learn, Compare, Then Connect

We're an independent resource — not a clinic. We help you understand the science and, if you choose, point you to independent licensed providers who handle any care.

Learn the Science

Read plain-English, citation-backed guides on what GLP3 (retatrutide) is, what its trials reported, and how GLP-1, GLP-1/GIP and GLP-3 compare.

Evidence-based

Connect With a Provider

If you want to explore treatment, we can refer you to independent, third-party licensed providers. Any evaluation, prescribing, and care is handled entirely by them — not by us.

Independent providers

Explore Research Compounds

Browse the Telos catalog of research-use-only compounds, sold strictly for laboratory and in-vitro research — not for human use, consumption, or therapeutic purposes.

Research use only

Clinical Evidence

Backed by Peer-Reviewed Science

The figures below are from landmark clinical trials published in leading medical journals. They describe what researchers observed in those studies — not results we offer, promise, or provide.

20.9%

Tirzepatide vs 3.1% Placebo

SURMOUNT-1, NEJM 2022

25.0%

Retatrutide (investigational) vs 3.9% Placebo

TRIUMPH-1, NEJM 2026

↓20%

Relative Risk of Major CV Events

SELECT (Semaglutide), NEJM 2023

14.9%

Semaglutide vs 2.4% Placebo

STEP 1, NEJM 2021

STEP 1 Trial: Semaglutide 2.4mg demonstrated 14.9% mean body weight reduction over 68 weeks versus 2.4% with placebo (NEJM, 2021).

SURMOUNT-1 Trial: Tirzepatide 15 mg produced 20.9% mean body weight reduction over 72 weeks versus 3.1% with placebo (NEJM, 2022).

Phase 2 Retatrutide: The triple agonist produced 24.2% mean body weight reduction at 48 weeks on the 12 mg dose versus 2.1% with placebo (NEJM, 2023).

TRIUMPH-1 (Phase 3): Retatrutide 12 mg produced 25.0% mean body weight reduction over 80 weeks versus 3.9% with placebo (NEJM, 2026). Retatrutide remains investigational and is not FDA-approved. See all published GLP3 trial results

SELECT Trial: Semaglutide reduced major adverse cardiovascular events by 20% in patients with overweight/obesity (NEJM, 2023).

Who We Are

An Independent Resource — Not a Clinic

Straight talk about what GLP3 Weight Loss is, and what it isn't.

What we do

Publish independent, citation-backed education on GLP-1 and GLP-3 weight-loss science, and offer a catalog of research-use-only compounds through our Telos line.

What we don't do

We are not a medical practice, pharmacy, or telehealth provider. We do not employ clinicians, see patients, diagnose, prescribe, or dispense peptide. No provider-patient relationship is created by using this site.

How referrals work

If you choose, we can connect you with independent, third-party licensed providers. We may be compensated for referrals. Any care decision is solely between you and that provider.

Retatrutide and other investigational compounds are not approved by the U.S. FDA. All Telos research compounds are sold strictly for laboratory and in-vitro research use only — not for human or veterinary use. Nothing on this page is medical advice; always consult your own licensed healthcare provider.

FAQ

Common Questions

General education about GLP-1 and GLP-3 weight-loss science. This is not medical advice.

What are GLP-1 and GLP-3 peptides?

GLP-1 receptor agonists (such as semaglutide and tirzepatide) are prescription peptides that can reduce appetite, slow gastric emptying, and regulate blood sugar. "GLP-3" is an informal term for next-generation triple-agonist investigational compounds like retatrutide that target GLP-1, GIP, and glucagon receptors. Retatrutide is investigational and not FDA-approved. This is general education, not medical advice. Full guide: What is GLP3 (retatrutide)?

How much weight did these peptides produce in clinical trials?

Published trials reported mean body-weight reductions of 14.9% with semaglutide 2.4 mg over 68 weeks (STEP 1), 20.9% with tirzepatide 15 mg over 72 weeks (SURMOUNT-1), and 25.0% with investigational retatrutide 12 mg over 80 weeks (TRIUMPH-1), versus 2.4%, 3.1% and 3.9%, respectively, with placebo. These were separate trials, not head-to-head comparisons. These are trial results, not outcomes we promise. Individual results vary, and any treatment decision should be made with your own licensed provider.

Does GLP3 Weight Loss prescribe peptide or provide care?

What is the Telos research-compound line?

How do I get a prescription if I'm interested in GLP-1 therapy?

What are the common side effects of GLP-1 peptides?

Your Next Step

Want to Explore GLP-1 or GLP-3 Therapy?

We can connect you with an independent, licensed provider who can evaluate whether treatment is right for you. Any care is handled entirely by that provider — not by us.

Independent providers

No obligation

We are not a medical provider

See My Options →

Independent provider referral · We may be compensated for referrals

The science ofGLP-1, GIP & GLP-3,made clear.